Why ImmunityBio Stock Is Trading Higher Thursday
Why ImmunityBio Stock Is Trading Higher Thursday
ImmunityBio, Inc. (NASDAQ:IBRX) shares are moving higher Thursday after the company announced insurance coverage of ANKTIVA across multiple states.
ImmunityBio，Inc.（纳斯达克：IBRX）股价在周四上涨，原因是该公司宣布其ANKTIVA已覆盖多个州的保险业。
The Details: ANKTIVA is a immunotherapy used to treat non-muscle invasive bladder cancer that was unresponsive to other specific treatments.
详情：ANKTIVA是一种免疫治疗，用于治疗非肌肉侵袭性膀胱癌，对其他特定治疗方法无反应。
The immunotherapy received FDA approval less than two months ago and the first doses of ANKTIVA have now been administered to patients located across the United States.
该免疫治疗获得FDA批准还不到两个月，第一批ANKTIVA剂量现已分布在美国各地的患者身上。
"In addition to its unique mechanism of action, ANKTIVA can be readily administered by urologists in their own offices and clinics enabling more patients to receive it in familiar settings from their own providers," said Richard Adcock, CEO of ImmunityBio.
ImmunityBio的首席执行官Richard Adcock表示：“除了其独特的作用机制外，ANKTIVA可以被泌尿科医生在他们自己的办公室和诊所里方便地进行管理，让更多的患者从自己的提供商那里得到治疗。”
FDA approval was based on a clinical trial involving 77 patients with a complete response rate of 62%.
FDA批准是基于77名患者的临床试验，在其中完全缓解率达到了62%。
Related Link: 19 Analysts Have This To Say About Sage Therapeutics
相关链接：19位分析师对Sage Therapeutics发表了这些看法
IBRX Price Action: ImmunityBio stock is trading 8.11% higher at $6.73, according to data from Benzinga Pro.
IBRX股票价格走势：根据Benzinga Pro的数据，ImmunityBio股票价格上涨8.11％，至6.73美元。
Image: Photo via Shutterstock.
图像:通过Shutterstock拍摄的照片。